These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 33032653)

  • 1. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
    Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined targeting of EGFR and HER2 against prostate cancer stem cells.
    Rossini A; Giussani M; Ripamonti F; Aiello P; Regondi V; Balsari A; Triulzi T; Tagliabue E
    Cancer Biol Ther; 2020 May; 21(5):463-475. PubMed ID: 32089070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
    Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
    Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
    Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells.
    Gruber M; Handle F; Culig Z
    Prostate; 2020 Feb; 80(3):267-273. PubMed ID: 31834633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.
    Zhang Y; Jin Z; Zhou H; Ou X; Xu Y; Li H; Liu C; Li B
    Cancer Med; 2016 Jun; 5(6):1251-8. PubMed ID: 26899963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
    Gravina GL; Marampon F; Petini F; Biordi L; Sherris D; Jannini EA; Tombolini V; Festuccia C
    Endocr Relat Cancer; 2011 Aug; 18(4):385-400. PubMed ID: 21551258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
    Lin JZ; Hameed I; Xu Z; Yu Y; Ren ZY; Zhu JG
    Oncol Rep; 2018 Oct; 40(4):2242-2250. PubMed ID: 30066906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
    Toner AP; McLaughlin F; Giles FJ; Sullivan FJ; O'Connell E; Carleton LA; Breen L; Dunne G; Gorman AM; Lewis JD; Glynn SA
    Br J Cancer; 2013 Oct; 109(8):2131-41. PubMed ID: 24052043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and application of a lung cancer stem cell model: antitumor drug screening and molecular mechanism of the inhibitory effects of sanguinarine.
    Yang J; Fang Z; Wu J; Yin X; Fang Y; Zhao F; Zhu S; Li Y
    Tumour Biol; 2016 Oct; 37(10):13871-13883. PubMed ID: 27485114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
    Kanwal R; Shukla S; Walker E; Gupta S
    Cancer Lett; 2018 Aug; 430():25-33. PubMed ID: 29775627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer.
    Chen Q; Song S; Wei S; Liu B; Honjo S; Scott A; Jin J; Ma L; Zhu H; Skinner HD; Johnson RL; Ajani JA
    Oncotarget; 2015 Sep; 6(28):25883-96. PubMed ID: 26317542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer.
    Wang KJ; Wang C; Dai LH; Yang J; Huang H; Ma XJ; Zhou Z; Yang ZY; Xu WD; Hua MM; Lu X; Zeng SX; Wang HQ; Zhang ZS; Cheng YQ; Liu D; Tian QQ; Sun YH; Xu CL
    Clin Cancer Res; 2019 Feb; 25(3):1070-1086. PubMed ID: 30397177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PGE
    Lin MC; Chen SY; He PL; Herschman H; Li HJ
    Int J Cancer; 2018 Sep; 143(6):1440-1455. PubMed ID: 29658109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
    Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
    Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
    Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
    Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
    Hwang JJ; Kim YS; Kim MJ; Kim DE; Jeong IG; Kim CS
    J Urol; 2010 Dec; 184(6):2557-64. PubMed ID: 21030039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.